Bolt Biotherapeutics director granted 5,000 options
Bolt Biotherapeutics director Kathleen LaPorte received a stock option grant for 5,000 shares of common stock.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Bolt Biotherapeutics director Kathleen LaPorte received a stock option grant for 5,000 shares of common stock. The option has an exercise price of $4.43 per share and expires on June 9, 2036. It vests on the earlier of June 9, 2027 or the day immediately before the next annual stockholder meeting, assuming continuous service. The option will vest in full if there is a change in control of Bolt Biotherapeutics.
Insider Trade Summary
Grant/Award: 5,000 shares
Grant/Award
1 txn
Insider
LAPORTE KATHLEEN
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 5,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 5,000 contracts (Direct)
Footnotes (1)
- F1. The shares subject to the option will vest on the earlier of June 9, 2027 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date; provided, however that the option will vest in full upon a change in control of the Issuer.
Key Figures
Option grant size: 5,000 shares
Exercise price: $4.43 per share
Expiration date: June 9, 2036
+1 more
4 metrics
Option grant size
5,000 shares
Stock Option (Right to Buy) granted to director
Exercise price
$4.43 per share
Conversion or exercise price of the option
Expiration date
June 9, 2036
Option expiration date
Vesting date
June 9, 2027
Latest vesting date or earlier before next annual meeting
Key Terms
Stock Option (Right to Buy), Grant, award, or other acquisition, change in control, vest
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
change in control financial
"the option will vest in full upon a change in control of the Issuer"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
vest financial
"The shares subject to the option will vest on the earlier of June 9, 2027"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Bolt Biotherapeutics (BOLT) report for Kathleen LaPorte?
Bolt Biotherapeutics reported that director Kathleen LaPorte received a grant of stock options for 5,000 shares. These options are a right to buy Bolt common stock under specified terms and are classified as a grant, award, or other acquisition.
What is the exercise price and size of the new Bolt Biotherapeutics (BOLT) option grant?
The new option grant to Kathleen LaPorte covers 5,000 shares of Bolt common stock at an exercise price of $4.43 per share. This price is the amount she would pay per share if she chooses to exercise the options in the future.
When do Kathleen LaPorte’s Bolt Biotherapeutics (BOLT) options vest?
The options vest on the earlier of June 9, 2027 or the day immediately before Bolt’s next annual stockholder meeting. Vesting requires that Kathleen LaPorte continue serving the company through that date under the terms disclosed.
What happens to the Bolt Biotherapeutics (BOLT) option grant if there is a change in control?
If there is a change in control of Bolt Biotherapeutics, the 5,000-share option granted to Kathleen LaPorte will vest in full. This means all option shares become exercisable upon such a change, according to the disclosed footnote terms.
How many Bolt Biotherapeutics (BOLT) options does Kathleen LaPorte hold after this grant?
After this grant, Kathleen LaPorte holds stock options covering 5,000 shares of Bolt common stock. This figure reflects the total option shares following the reported transaction, as stated in the Form 4 transaction details.
AI-generated analysis. How Rhea-AI works. Not financial advice.
